Effect of miR-29a Inhibition on Ventricular Hypertrophy Induced by Pressure Overload

Cell Biochemistry and Biophysics

Volumn 71, Issue 2, 2015, Pages 821-826

  Han, Wei ^a   Han, Yancong ^a   Liu, Xiaokun ^a   Shang, Xiaoming ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Hypertension; miR 29a; Ventricular hypertrophy; Ventricular remodeling

Indexed keywords

MICRORNA; MIRN29 MICRORNA, HUMAN; OLIGONUCLEOTIDE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; FEMALE; FIBROSIS; GENETICS; HEART VENTRICLE; HUMAN; HYPERTENSION; HYPERTROPHY; MALE; MIDDLE AGED; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; FEMALE; FIBROSIS; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY; MALE; MICE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDES;

EID: 84925485204     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0269-x     Document Type: Article

References (22)

1. Opie, L. H., Commerford, P. J., Gersh, B. J., & Pfeffer, M. A. (2006). Controversies in ven- tricular remodelling. Lancet,367, 356–367.
2. Kindo, M., Gerelli, S., Bouitbir, J., Charles, A-L., Zoll, J., Minh, TH., Monassier, L., Favret, F., Piquard, F., Geny, B. (2012) Pressure overload-induced mild cardiac hypertrophy reduces left ventricular trans mural differences in mitochondrial respiratory chain activity and increases oxidative stress. Frontiers in physiology, article 332.
3. Zhou, S., Liu, Y., Prater, K., Zheng, Y., & Cai, L. (2013). Roles of microRNAs in pressure overload- and ischemia-related myocardial remodeling. Life Sciences,93(23), 855–862.
4. Elzenaar, I., Pinto, Y. M., & van Oort, R. J. (2013). MicroRNAs in heart failure: new targets in disease management. Clinical Pharmacology and Therapeutics,94(4), 480–489.
5. He, F., Peng, F., Xia, X., Zhao, C., Luo, Q., Guan, W., et al. (2014). MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia,57(8), 1726–1736.
6. Xin, X., Zhang, Y., Liu, X., Xin, H., Cao, Y., & Geng, M. (2014). MicroRNA in hepatic fibrosis and cirrhosis. Frontiers in bioscience,19, 1418–1424.
7. Tu, X., Zhang, H., Zhang, J., Zhao, S., Zheng, X., Zhang, Z., et al. (2014). MicroRNA-101 suppresses liver fibrosis by targeting the TGFbeta signalling pathway. Journal of Pathology,234(1), 46–59.
8. Roncarati, R., Anselmi, C. V., Losi, M. A., Papa, L., Cavarretta, E., Martins, P. D. C., et al. (2014). Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology,63(9), 920–927.
9. Wu, J., You, J., Jiang, G., Li, L., Guan, A., Ye, Y., et al. (2012). Noninvasive estimation of infarct size in a mouse model of myocardial infarction by echocardiographic coronary perfusion. Journal of Ultrasound in Medicine,31, 1111–1121.
10. Suzuki, T., Kado, S., Ando, M., Nagata, Y., Iwata, S., Kobayashi, T., et al. (2009). Spontaneous cardiac hypertrophy in a Crl:CD(SD) rat, case report. Journal of Toxicologic Pathology,22, 83–87.
11. Wang, B., Komers, R., Carew, R., Winbanks, C. E., Xu, B., Herman-Edelstein, M., et al. (2012). Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. Journal of the American Society of Nephrology,23(2), 252–265.
12. Haugaa, K. H., Bos, J. M., Borkenhagen, E., Tarrell, R. F., Morlan, B. W., Caraballo, P. J., et al. (2014). Impact of Left Ventricular Hypertrophy on QT Prolongation and Associated Mortality. Heart Rhythm,0, 2–9.
13. Wang, S., Xue, H., Zou, Y., Sun, K., Fu, C., Wang, H., et al. (2014). Left ventricular hypertrophy, abnormal ventricular geometry and relative wall thickness are associated with increased risk of stroke in hypertensive patients among the Han Chinese. Hypertension Research. doi:10.1038/hr.2014.88.
14. Drazner, M. H. (2011). The progression of hypertensive heart disease. Circulation,123, 327–334.
15. Wei, C., Kim, I. K., Kumar, S., Jayasinghe, S., Hong, N., Castoldi, G., et al. (2013). NF-kappaB mediated miR-26a regulation in cardiac fibrosis. Journal of Cellular Physiology,228(7), 1433–1442.
16. Hoff, J., Bates, E., Barnes, B., Glickman, M., & Margolis, T. (1973). Traumatic subdural hygroma. Journal of Trauma,13(10), 870–876.
17. Li, C., Li, X., Gao, X., Zhang, R., Zhang, Y., Liang, H., et al. (2014). MicroRNA-328 as a regulator of cardiac hypertrophy. International Journal of Cardiology,173(2), 268–276.
18. Ramdas, V., McBride, M., Denby, L., & Baker, A. H. (2013). Canonical transforming growth factor-beta signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. American Journal of Pathology,183(6), 1885–1896.
19. Maurer, B., Stanczyk, J., Jungel, A., Akhmetshina, A., Trenkmann, M., Brock, M., et al. (2010). MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism,62(6), 1733–1743.
20. Roderburg, C., Urban, G. W., Bettermann, K., Vucur, M., Zimmermann, H., Schmidt, S., et al. (2011). Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology,53(1), 209–218.
21. Zhang, Y., Huang, X. R., Wei, L. H., Chung, A. C., Yu, C. M., & Lan, H. Y. (2014). miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Molecular Therapy,22(5), 974–985.
22. Fan, D., Takawale, A., Lee, J., & Kassiri, Z. (2012). Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair,5, 15. doi:10.1186/1755-1536-5-15.